Antibody Information
General Information of This Antibody
Antibody ID | ANI0BTNLJ |
|||||
---|---|---|---|---|---|---|
Antibody Name | IMAB362 |
|||||
Organization | Ganymed Pharmaceuticals AG |
|||||
Indication | Pancreatic cancer; Gastric cancer |
|||||
Synonyms |
Zolbetuximab
Click to Show/Hide
|
|||||
Antibody Type | Monoclonal antibody (mAb) |
|||||
Antibody Subtype | Chimeric IgG1-kappa |
|||||
Antigen Name | Claudin-18.2 (CLDN18.2) |
Antigen Info | ||||
ChEMBI ID | ||||||
DrugBank ID | ||||||
Click to Show/Hide the Sequence Information of This Antibody | ||||||
Heavy Chain Sequence |
QVQLQQPGAELVRPGASVKLSCKASGYTFTSYWINWVKQRPGQGLEWIGNIYPSDSYTNY
NQKFKDKATLTVDKSSSTAYMQLSSPTSEDSAVYYCTRSWRGNSFDYWGQGTTLTVSSAS TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
Heavy Chain Varible Domain |
QVQLQQPGAELVRPGASVKLSCKASGYTFTSYWINWVKQRPGQGLEWIGNIYPSDSYTNY
NQKFKDKATLTVDKSSSTAYMQLSSPTSEDSAVYYCTRSWRGNSFDYWGQGTTLTVSS Click to Show/Hide
|
|||||
Heavy Chain Constant Domain 1 |
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRV Click to Show/Hide
|
|||||
Heavy Chain Constant Domain 2 |
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK Click to Show/Hide
|
|||||
Heavy Chain Constant Domain 3 |
GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
Heavy Chain Hinge Region |
EPKSCDKTHTCPPCP
Click to Show/Hide
|
|||||
Heavy Chain CDR 1 |
GYTFTSYW
Click to Show/Hide
|
|||||
Heavy Chain CDR 2 |
IYPSDSYT
Click to Show/Hide
|
|||||
Heavy Chain CDR 3 |
TRSWRGNSFDY
Click to Show/Hide
|
|||||
Light Chain Sequence |
DIVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTR
ESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPFTFGSGTKLEIKRTVAAPS VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
Light Chain Varible Domain |
DIVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTR
ESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPFTFGSGTKLEIK Click to Show/Hide
|
|||||
Light Chain Constant Domain |
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
Light Chain CDR 1 |
QSLLNSGNQKNY
Click to Show/Hide
|
|||||
Light Chain CDR 2 |
WAS
Click to Show/Hide
|
|||||
Light Chain CDR 3 |
QNDYSYPFT
Click to Show/Hide
|
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
IMAB362-MC-Val-Cit-PAB-MMAE [Investigative]
Discovered Using Patient-derived Xenograft Model
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 63.30% (Day 67) | Positive CLDN18.2 expression (CLDN18.2 +++/++) | ||
Method Description |
Conjugates of the exemplary antibodies were tested using an established PDX model of pancreatic cancer cell implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 5 mg/kg of one of the conjugates listed above or with PBS only.
|
||||
In Vivo Model | Pancreatic cancer PDX model |
Revealed Based on the Cell Line Data
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
501 ng/mL
|
Positive CLDN18.2 expression (CLDN18.2 +++/++) | ||
Method Description |
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
|
||||
In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 |
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.